Real-world risk assessment and treatment initiation among patients with myelofibrosis at community oncology practices in the United States. Ann Hematol. 2020 Nov;99(11):2555-2564. doi: 10.1007/s00277-020-04055-w. Epub 2020 May 7.
Care Coordination Between Prescribers and the Specialty Pharmacy for Multiple Myeloma: Qualitative Insights Into Designing a Quality Improvement Program for Multisite Community Oncology Practices. J Clin Pathways. 2020;6(6):43-48. doi:10.25270/jcp.2020.8.00002.
McCullough SW, Blaisdell D, Kish JK, Laney J, Valuck T, Dickson N, Berdeja JG, Patton JF, Copher R, Powers A.
Perceptions of community hematologists/oncologists on barriers to chimeric antigen receptor T-cell therapy for the treatment of diffuse large B-cell lymphoma. Immunotherapy. 2020 Jul;12(10):725-732. doi: 10.2217/imt-2020-0118. Epub 2020 Jun 18.
Gajra A, Jeune-Smith Y, Kish J, Yeh TC, Hime S, Feinberg B.
Lenvatinib and Subsequent Therapy for Radioactive Iodine-Refractory Differentiated Thyroid Cancer: A Real-World Study of Clinical Effectiveness in the United States. Adv Ther. 2020 Jun;37(6):2841-2852. doi: 10.1007/s12325-020-01362-6. Epub 2020 May 7.
Kish JK, Chatterjee D, Wan Y, Yu HT, Liassou D, Feinberg BA.
Comparative Effectiveness of Palliative Chemotherapy in Metastatic Breast Cancer: A Real-World Evidence Analysis. Oncologist. 2020 Apr;25(4):319-326. doi: 10.1634/theoncologist.2019-0699. Epub 2020 Jan 17.
Feinberg B, Kish J, Dokubo I, Wojtynek J, Gajra A, Lord K.
Observational study of clinical outcomes of eribulin mesylate in metastatic breast cancer after cyclin-dependent kinase 4/6 inhibitor therapy. Future Oncol. 2019 Dec;15(34):3935-3944. doi: 10.2217/fon-2019-0537. Epub 2019 Oct 29.
Mougalian SS, Feinberg BA, Wang E, Alexis K, Chatterjee D, Knoth RL, Nero D, Miller T, Liassou D, Kish JK.
Real-world treatment patterns, cost of care and effectiveness of therapies for patients with squamous cell carcinoma of head and neck pre and post approval of immuno-oncology agents. J Med Econ. 2020 Feb;23(2):125-131. doi: 10.1080/13696998.2019.1676760. Epub 2019 Oct 18.
Abraham P, Kish JK, Korytowsky B, Radtchenko J, Singh P, Shaw J, Feinberg B.
Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States. J Manag Care Spec Pharm. 2019 Aug;25(8):869-877. doi: 10.18553/jmcp.2019.18442. Epub 2019 Apr 4.
Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes. Leuk Lymphoma. 2019 Aug;60(8):2050-2055. doi: 10.1080/10428194.2018.1551538. Epub 2019 Jan 14.
Clinical benefit of treatment with eribulin mesylate for metastatic triple-negative breast cancer: Long-term outcomes of patients treated in the US community oncology setting. Cancer Med. 2018 Sep;7(9):4371-4378. doi: 10.1002/cam4.1705. Epub 2018 Jul 31.
Mougalian SS, Copher R, Kish JK, McAllister L, Wang Z, Broscious M, Garofalo D, Radtchenko J, Feinberg BA.
Real-world evidence analysis of palbociclib prescribing patterns for patients with advanced/metastatic breast cancer treated in community oncology practice in the USA one year post approval. Breast Cancer Res. 2018 May 2;20(1):37. doi: 10.1186/s13058-018-0958-2.